Pliant Therapeutics, Inc. (PLRX)
NASDAQ: PLRX · Real-Time Price · USD
1.210
0.00 (0.00%)
At close: Apr 28, 2026, 4:00 PM EDT
1.200
-0.010 (-0.83%)
After-hours: Apr 28, 2026, 4:09 PM EDT
Company Description
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors.
The company’s lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of αvß8 and αvß1 integrins that is in Phase 1a/1b for the treatment of solid tumors.
It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based target-mediated drug delivery.
Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Pliant Therapeutics, Inc.
| Country | United States |
| Founded | 2015 |
| IPO Date | Jun 3, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 49 |
| CEO | Bernard Coulie |
Contact Details
Address: 331 Oyster Point Boulevard South San Francisco, California 94080 United States | |
| Phone | 650 481 6770 |
| Website | pliantrx.com |
Stock Details
| Ticker Symbol | PLRX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001746473 |
| CUSIP Number | 729139105 |
| ISIN Number | US7291391057 |
| Employer ID | 47-4272481 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Bernard Coulie M.B.A., M.D., Ph.D. | President, Chief Executive Officer and Director |
| Dr. Keith Lamont Cummings M.B.A., M.D. | Chief Financial Officer |
| Minnie Kuo | Chief Operating Officer |
| Dr. Rik Derynck Ph.D. | Scientific Founder and Member of Scientific Advisory Board |
| Dean Sheppard M.D. | Scientific Founder and Member of Scientific Advisory Board |
| Hal Chapman M.D. | Scientific Founder and Member of Scientific Advisory Board |
| Delphine Imbert Ph.D. | Chief Technical Officer |
| Christopher S. Keenan | Vice President of Investor Relations and Corporate Communications |
| Monica Sandberg Ph.D. | Vice President, Regulatory and Compliance |
| Lily Cheung | Chief Human Resources Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 22, 2026 | ARS | Filing |
| Apr 22, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 22, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 17, 2026 | 8-K | Current Report |
| Apr 6, 2026 | EFFECT | Notice of Effectiveness |
| Mar 30, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| Mar 30, 2026 | 8-K | Current Report |
| Mar 11, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 11, 2026 | 8-K | Current Report |
| Mar 11, 2026 | 10-K | Annual Report |